Publicaciones en colaboración con investigadores/as de French Institute of Health and Medical Research (287)

2024

  1. High prevalence of venous thrombotic events in Cushing’s syndrome: data from ERCUSYN and details in relation to surgery

    European Journal of Endocrinology, Vol. 190, Núm. 1, pp. 75-85

  2. The immunopathological landscape of human pre-TCRa deficiency: From rare to common variants

    Science, Vol. 383, Núm. 6686

2023

  1. Glomerular diseases in pregnancy: pragmatic recommendations for clinical management

    Kidney International, Vol. 103, Núm. 2, pp. 264-281

  2. Identifying unmet needs and challenges in the definition of a plaque in mycosis fungoides: An EORTC-CLTG/ISCL survey

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 4, pp. 680-688

  3. Interferon gamma-1b for the prevention of hospital-acquired pneumonia in critically ill patients: a phase 2, placebo-controlled randomized clinical trial

    Intensive Care Medicine, Vol. 49, Núm. 5, pp. 530-544

  4. Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial

    The Lancet Child and Adolescent Health, Vol. 7, Núm. 10, pp. 718-727

  5. Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial

    eClinicalMedicine, Vol. 60

  6. Pneumocystis jirovecii pneumonia in intensive care units: a multicenter study by ESGCIP and EFISG

    Critical Care, Vol. 27, Núm. 1

  7. Population pharmacokinetics of unbound and total dolutegravir concentrations in children aged 12 <FOR VERIFICATION>years and older: a PK substudy of the SMILE trial

    Journal of Antimicrobial Chemotherapy, Vol. 78, Núm. 4, pp. 1041-1049

  8. Predictors of treatment switching in the Big Multiple Sclerosis Data Network

    Frontiers in Neurology, Vol. 14

  9. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

    Genome Medicine, Vol. 15, Núm. 1

  10. Suicidality Treatment Occurring in Paediatrics (STOP) Medication Suicidality Side Effects Scale in young people in two cohorts across Europe

    BMJ Open, Vol. 13, Núm. 12

2022

  1. Cardiac and Pulmonary Vascular Dysfunction in Vitamin D-Deficient Bmpr2-Mutant Rats

    American journal of respiratory cell and molecular biology

  2. Childhood Maltreatment, Educational Attainment, and IQ: Findings from a Multicentric Case-control Study of First-episode Psychosis (EU-GEI)

    Schizophrenia Bulletin, Vol. 48, Núm. 3, pp. 575-589

  3. Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial

    Frontiers in Oncology, Vol. 12

  4. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up

    European Heart Journal, Vol. 43, Núm. 11, pp. 1059-1103

  5. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

    The Lancet Gastroenterology and Hepatology, Vol. 7, Núm. 2, pp. 128-140

  6. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    Cardiovascular research, Vol. 118, Núm. 6, pp. 1385-1412

  7. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    European Heart Journal, Vol. 43, Núm. 11, pp. 1033-1058

  8. Facial Emotion Recognition in Psychosis and Associations With Polygenic Risk for Schizophrenia: Findings From the Multi-Center EU-GEI Case-Control Study

    Schizophrenia bulletin, Vol. 48, Núm. 5, pp. 1104-1114